Format

Send to

Choose Destination
J Infect Dis. 2013 Mar;207 Suppl 1:S7-S12. doi: 10.1093/infdis/jis762.

Immune responses to hepatitis C virus (HCV) infection and the prospects for an effective HCV vaccine or immunotherapies.

Author information

1
Gastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. glauer@helix.mgh.harvard.edu

Abstract

Infection with hepatitis C virus (HCV) typically leads to persistent infection, with >170 million people estimated to be affected worldwide, putting them at risk for chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Importantly, 20%-30% of individuals are able to control the virus spontaneously, usually within 6 months of exposure. This suggests that HCV vaccines and immunotherapies are a distinct possibility. We discuss here the role of T cells in controlling HCV, the gaps in our understanding of protective HCV immunity, and the recent introduction of a HCV T-cell vaccine into clinical trials.

PMID:
23390305
DOI:
10.1093/infdis/jis762
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center